Altamira Therapeutics Stock Performance
| CYTO Stock | USD 0.44 0.03 7.32% |
The firm shows a Beta (market volatility) of -0.17, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Altamira Therapeutics are expected to decrease at a much lower rate. During the bear market, Altamira Therapeutics is likely to outperform the market. At this point, Altamira Therapeutics has a negative expected return of -1.02%. Please make sure to confirm Altamira Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Altamira Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Altamira Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 15.4 K |
Altamira |
Altamira Therapeutics Relative Risk vs. Return Landscape
If you would invest 91.00 in Altamira Therapeutics on August 24, 2024 and sell it today you would lose (47.00) from holding Altamira Therapeutics or give up 51.65% of portfolio value over 90 days. Altamira Therapeutics is currently does not generate positive expected returns and assumes 4.716% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Altamira, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Altamira Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Altamira Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Altamira Therapeutics, and traders can use it to determine the average amount a Altamira Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2156
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CYTO |
Estimated Market Risk
| 4.72 actual daily | 42 58% of assets are more volatile |
Expected Return
| -1.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.22 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Altamira Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Altamira Therapeutics by adding Altamira Therapeutics to a well-diversified portfolio.
Altamira Therapeutics Fundamentals Growth
Altamira Stock prices reflect investors' perceptions of the future prospects and financial health of Altamira Therapeutics, and Altamira Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Altamira Stock performance.
| Return On Equity | -3.69 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 2.02 M | ||||
| Shares Outstanding | 3.78 M | ||||
| Price To Book | 0.26 X | ||||
| Price To Sales | 0.64 X | ||||
| EBITDA | (1.35 M) | ||||
| Cash And Equivalents | 984.19 K | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 99.66 K | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 2.37 X | ||||
| Cash Flow From Operations | (11.51 M) | ||||
| Earnings Per Share | 1.94 X | ||||
| Total Asset | 7.69 M | ||||
| Retained Earnings | (18.05 M) | ||||
About Altamira Therapeutics Performance
By examining Altamira Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Altamira Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Altamira Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda. Altamira Therapeutics is traded on NASDAQ Exchange in the United States.Things to note about Altamira Therapeutics performance evaluation
Checking the ongoing alerts about Altamira Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Altamira Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Altamira Therapeutics generated a negative expected return over the last 90 days | |
| Altamira Therapeutics has some characteristics of a very speculative penny stock | |
| Altamira Therapeutics has high historical volatility and very poor performance | |
| Altamira Therapeutics currently holds 99.66 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Altamira Therapeutics has a current ratio of 0.75, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Altamira Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (3.87 M) with loss before overhead, payroll, taxes, and interest of (2.18 M). | |
| Altamira Therapeutics currently holds about 984.19 K in cash with (11.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Altamira Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Altamira Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Altamira Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Altamira Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Altamira Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Altamira Therapeutics' stock. These opinions can provide insight into Altamira Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.